Greg Guyer, Ph.D, joined BioMarin in May 2020 and currently serves as our Chief Technical Officer, Manufacturing and Technical Operations, responsible for overseeing our manufacturing, process development, quality, supply chain, engineering and analytical chemistry departments.
From 2015 to 2019, Dr. Guyer served in a number of increasingly responsible positions at Bristol Myers Squibb (BMS), primarily leading all of operations and biologic development. Prior to BMS, he worked for Merck & Co., Inc., from 1994 to 2015, leading various global organizations in biologic and pharmaceutical operations, quality, regulatory, emerging markets strategy and enterprise systems.
Dr. Guyer earned a Ph.D. in analytical chemistry from American University, a B.S. in chemistry from the University of Georgia and an M.B.A. from Lehigh University. He currently serves on the Board of Directors for the University of Georgia Research Foundation. In addition, Dr. Guyer also serves as executive Leader Liaison to the BioMarin PRIDE Employee Resource Group.
We maximize the impact of genetic innovation to develop transformative therapies.
We recently presented an update on our pipeline to the investor community. View the replay on our Investor Relations site.
View Now Our Pipeline ⌃